Search

Your search keyword '"Jassem, Jacek"' showing total 1,355 results
Start Over Author "Jassem, Jacek"
1,355 results on '"Jassem, Jacek"'

3. Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study

Author

McLeod, Megan, Torode, Julie, Leung, Kari, Bhoo-Pathy, Nirmala, Booth, Christopher, Chakowa, Jade, Gralow, Julie, Ilbawi, Andre, Jassem, Jacek, Parkes, Jeannette, Mallafré-Larrosa, Merixtell, Mutebi, Miriam, Pramesh, CS, Sengar, Manju, Tsunoda, Audrey, Unger-Saldaña, Karla, Vanderpuye, Verna, Yusuf, Aasim, Sullivan, Richard, and Aggarwal, Ajay

Published
2024
Full Text
View/download PDF

4. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

Author

Bearz, Alessandra, Martini, Jean-François, Jassem, Jacek, Kim, Sang-We, Chang, Gee-Chen, Shaw, Alice T., Shepard, Deborah A., Dall’O’, Elisa, Polli, Anna, Thurm, Holger, Zalcman, Gerard, Garcia Campelo, Maria Rosario, Penkov, Konstantin, Hayashi, Hidetoshi, and Solomon, Benjamin J.

Published
2023
Full Text
View/download PDF

5. A View from the past into our collective future: the oncofertility consortium vision statement.

Author

Woodruff, Teresa K, Ataman-Millhouse, Lauren, Acharya, Kelly S, Almeida-Santos, Teresa, Anazodo, Antoinette, Anderson, Richard A, Appiah, Leslie, Bader, Joy, Becktell, Kerri, Brannigan, Robert E, Breech, Lesley, Bourlon, Maria T, Bumbuliene, Žana, Burns, Karen, Campo-Engelstein, Lisa, Campos, Jacira R, Centola, Grace M, Chehin, Mauricio Barbour, Chen, Diane, De Vos, Michel, Duncan, Francesca E, El-Damen, Ahmed, Fair, Douglas, Famuyiwa, Yemi, Fechner, Patricia Y, Fontoura, Paula, Frias, Olivia, Gerkowicz, Sabrina A, Ginsberg, Jill, Gracia, Clarisa R, Goldman, Kara, Gomez-Lobo, Veronica, Hazelrigg, Brent, Hsieh, Michael H, Hoyos, Luis R, Hoyos-Martinez, Alfonso, Jach, Robert, Jassem, Jacek, Javed, Murid, Jayasinghe, Yasmin, Jeelani, Roohi, Jeruss, Jacqueline S, Kaul-Mahajan, Nalini, Keim-Malpass, Jessica, Ketterl, Tyler G, Khrouf, Mohamed, Kimelman, Dana, Kusuhara, Atsuko, Kutteh, William H, Laronda, Monica M, Lee, Jung Ryeol, Lehmann, Vicky, Letourneau, Joseph M, McGinnis, Lynda K, McMahon, Eileen, Meacham, Lillian R, Mijangos, Monserrat Fabiola Velez, Moravek, Molly, Nahata, Leena, Ogweno, George Moses, Orwig, Kyle E, Pavone, Mary Ellen, Peccatori, Fedro Alessandro, Pesce, Romina Ileana, Pulaski, Hanna, Quinn, Gwendolyn, Quintana, Ramiro, Quintana, Tomas, de Carvalho, Bruno Ramalho, Ramsey-Goldman, Rosalind, Reinecke, Joyce, Reis, Fernando M, Rios, Julie, Rhoton-Vlasak, Alice S, Rodriguez-Wallberg, Kenny A, Roeca, Cassandra, Rotz, Seth J, Rowell, Erin, Salama, Mahmoud, Saraf, Amanda J, Scarella, Anibal, Schafer-Kalkhoff, Tara, Schmidt, Deb, Senapati, Suneeta, Shah, Divya, Shikanov, Ariella, Shnorhavorian, Margarett, Skiles, Jodi L, Smith, James F, Smith, Kristin, Sobral, Fabio, Stimpert, Kyle, Su, H Irene, Sugimoto, Kouhei, Suzuki, Nao, Thakur, Mili, Victorson, David, Viale, Luz, Vitek, Wendy, and Wallace, W Hamish

Subjects
Fertility preservation, Oncofertility, cancer, Genetics, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
Abstract

PurposeToday, male and female adult and pediatric cancer patients, individuals transitioning between gender identities, and other individuals facing health extending but fertility limiting treatments can look forward to a fertile future. This is, in part, due to the work of members associated with the Oncofertility Consortium.MethodsThe Oncofertility Consortium is an international, interdisciplinary initiative originally designed to explore the urgent unmet need associated with the reproductive future of cancer survivors. As the strategies for fertility management were invented, developed or applied, the individuals for who the program offered hope, similarly expanded. As a community of practice, Consortium participants share information in an open and rapid manner to addresses the complex health care and quality-of-life issues of cancer, transgender and other patients. To ensure that the organization remains contemporary to the needs of the community, the field designed a fully inclusive mechanism for strategic planning and here present the findings of this process.ResultsThis interprofessional network of medical specialists, scientists, and scholars in the law, medical ethics, religious studies and other disciplines associated with human interventions, explore the relationships between health, disease, survivorship, treatment, gender and reproductive longevity.ConclusionThe goals are to continually integrate the best science in the service of the needs of patients and build a community of care that is ready for the challenges of the field in the future.

Published
2021

6. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Author

Paz-Ares, Luis G., Ciuleanu, Tudor-Eliade, Cobo, Manuel, Bennouna, Jaafar, Schenker, Michael, Cheng, Ying, Juan-Vidal, Oscar, Mizutani, Hideaki, Lingua, Alejo, Reyes-Cosmelli, Felipe, Reinmuth, Niels, Menezes, Juliana, Jassem, Jacek, Protsenko, Svetlana, Richardet, Eduardo, Felip, Enriqueta, Feeney, Kynan, Zurawski, Bogdan, Alexandru, Aurelia, de la Mora Jimenez, Emmanuel, Dakhil, Shaker, Lu, Shun, Reck, Martin, John, Thomas, Hu, Nan, Zhang, Xiaoqing, Sylvester, Judi, Eccles, Laura J., Grootendorst, Diederik J., Balli, David, Neely, Jaclyn, and Carbone, David P.

Published
2023
Full Text
View/download PDF

7. European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission

Author

Lawler, Mark, Davies, Lynne, Oberst, Simon, Oliver, Kathy, Eggermont, Alexander, Schmutz, Anna, La Vecchia, Carlo, Allemani, Claudia, Lievens, Yolande, Naredi, Peter, Cufer, Tanja, Aggarwal, Ajay, Aapro, Matti, Apostolidis, Kathi, Baird, Anne-Marie, Cardoso, Fatima, Charalambous, Andreas, Coleman, Michel P, Costa, Alberto, Crul, Mirjam, Dégi, Csaba L, Di Nicolantonio, Federica, Erdem, Sema, Geanta, Marius, Geissler, Jan, Jassem, Jacek, Jagielska, Beata, Jonsson, Bengt, Kelly, Daniel, Kelm, Olaf, Kolarova, Teodora, Kutluk, Tezer, Lewison, Grant, Meunier, Françoise, Pelouchova, Jana, Philip, Thierry, Price, Richard, Rau, Beate, Rubio, Isabel T, Selby, Peter, Južnič Sotlar, Maja, Spurrier-Bernard, Gilliosa, van Hoeve, Jolanda C, Vrdoljak, Eduard, Westerhuis, Willien, Wojciechowska, Urszula, and Sullivan, Richard

Published
2023
Full Text
View/download PDF

8. Real-world treatment outcomes in patients with HR+ HER2- advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy.

Author

Duchnowska, Renata, primary, Soter, Katarzyna, additional, Smok-Kalwat, Jolanta, additional, Grela-Wojewoda, Aleksandra, additional, Winsko-Szczęsnowicz, Karolina, additional, Pogoda, Katarzyna, additional, Kade, Grzegorz, additional, Danielewicz, Iwona, additional, Szymanowski, Bartosz, additional, Kiszka, Joanna, additional, Streb, Joanna, additional, Kalinka, Ewa, additional, Łacko, Aleksandra, additional, Żubrowska, Justyna, additional, Ziobro, Marek, additional, Czartoryska-Arlukowicz, Bogumila, additional, Jurczyk, Michał, additional, Lewandowski, Tomasz, additional, Jassem, Jacek, additional, and Bieńkowski, Michał, additional

Published
2024
Full Text
View/download PDF

10. Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases

Author

Nicoś, Marcin, Harbers, Luuk, Patrucco, Enrico, Kramer-Drauberg, Maximilian, Zhang, Xiaolu, Voena, Claudia, Kowalczyk, Anna, Bożyk, Aleksandra, Pęksa, Rafał, Jarosz, Bożena, Szumiło, Justyna, Simonetti, Michele, Żuk, Monika, Wasąg, Bartosz, Reszka, Katarzyna, Duchnowska, Renata, Milanowski, Janusz, Chiarle, Roberto, Bienko, Magda, Krawczyk, Paweł, Jassem, Jacek, Ambrogio, Chiara, and Crosetto, Nicola

Published
2022
Full Text
View/download PDF

11. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

Author

Saad, Fred, Thiery-Vuillemin, Antoine, Wiechno, Pawel, Alekseev, Boris, Sala, Nuria, Jones, Robert, Kocak, Ivo, Chiuri, Vincenzo Emanuele, Jassem, Jacek, Fléchon, Aude, Redfern, Charles, Kang, Jinyu, Burgents, Joseph, Gresty, Christopher, Degboe, Arnold, and Clarke, Noel W

Published
2022
Full Text
View/download PDF

15. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Author

Jassem, Jacek, de Marinis, Filippo, Giaccone, Giuseppe, Vergnenegre, Alain, Barrios, Carlos H., Morise, Masahiro, Felip, Enriqueta, Oprean, Cristina, Kim, Young-Chul, Andric, Zoran, Mocci, Simonetta, Enquist, Ida, Komatsubara, Kimberly, McCleland, Mark, Kuriki, Hiroshi, Villalobos, Monette, Phan, See, Spigel, David R., and Herbst, Roy S.

Published
2021
Full Text
View/download PDF

18. The European Code of Cancer Practice

Author

Lawler, Mark, Oliver, Kathy, Gijssels, Stefan, Aapro, Matti, Abolina, Agnese, Albreht, Tit, Erdem, Sema, Geissler, Jan, Jassem, Jacek, Karjalainen, Sakari, La Vecchia, Carlo, Lievens, Yolande, Meunier, Françoise, Morrissey, Mike, Naredi, Peter, Oberst, Simon, Poortmans, Philip, Price, Richard, Sullivan, Richard, Velikova, Galina, Vrdoljak, Eduard, Wilking, Nils, Yared, Wendy, and Selby, Peter

Published
2021
Full Text
View/download PDF

19. Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

Author

García‐Carbonero, Rocío, van Cutsem, Eric, Rivera, Fernando, Jassem, Jacek, Gore, Ira, Tebbutt, Niall, Braiteh, Fadi, Argiles, Guillem, Wainberg, Zev A, Funke, Roel, Anderson, Maria, McCall, Bruce, Stroh, Mark, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, and Hurwitz, Herbert

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Digestive Diseases, Colo-Rectal Cancer, Biotechnology, Clinical Trials and Supportive Activities, Cancer, Prevention, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Calcium-Binding Proteins, Colorectal Neoplasms, Disease-Free Survival, EGF Family of Proteins, Endothelial Growth Factors, Female, Fluorouracil, Gene Expression Regulation, Neoplastic, Humans, Leucovorin, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Lessons learnedThese negative phase II results for parsatuzumab highlight the challenges of developing an agent intended to enhance the efficacy of vascular endothelial growth factor inhibition without the benefit of validated pharmacodynamic biomarkers or strong predictive biomarker hypotheses.Any further clinical development of anti-EGFL7 is likely to require new mechanistic insights and biomarker development for antiangiogenic agents.BackgroundEGFL7 (epidermal growth factor-like domain 7) is a tumor-enriched vascular extracellular matrix protein that supports endothelial cell survival. This phase II trial evaluated the efficacy of parsatuzumab (also known as MEGF0444A), a humanized anti-EGFL7 IgG1 monoclonal antibody, in combination with modified FOLFOX6 (mFOLFOX6) (folinic acid, 5-fluorouracil, and oxaliplatin) bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).MethodsOne-hundred twenty-seven patients were randomly assigned to parsatuzumab, 400 mg, or placebo, in combination with mFOLFOX6 plus bevacizumab, 5 mg/kg. Treatment cycles were repeated every 2 weeks until disease progression or unacceptable toxicity for a maximum of 24 months, with the exception of oxaliplatin, which was administered for up to 8 cycles.ResultsThe progression-free survival (PFS) hazard ratio was 1.17 (95% confidence interval [CI], 0.71-1.93; p = .548). The median PFS was 12 months for the experimental arm versus 11.9 months for the control arm. The hazard ratio for overall survival was 0.97 (95% CI, 0.46-2.1; p = .943). The overall response rate was 59% in the parsatuzumab arm and 64% in the placebo arm. The adverse event profile was similar in both arms.ConclusionsThere was no evidence of efficacy for the addition of parsatuzumab to the combination of bevacizumab and chemotherapy for first-line mCRC. The Oncologist 2017;22:375-e30.

Published
2017

20. ALK alterations in salivary gland carcinomas

Author

Majewska, Hanna, Gorczyński, Adam, Czapiewski, Piotr, Menon, Roopika, Mueller, Judith, Lakis, Sotirios, Heuckmann, Johannes M., Laco, Jan, Gupta, Ruta, Andreasen, Simon, Stodulski, Dominik, Iliszko, Mariola, Dziadziuszko, Rafał, Jassem, Jacek, Heukamp, Lukas C., and Biernat, Wojciech

Published
2021
Full Text
View/download PDF

21. The effect of gD-derived peptides on T cell immune response mediated by BTLAHVEM protein complex in melanoma patients.

Author

Wojciechowicz, Karolina, Kuncewicz, Katarzyna, Rutkowski, Jacek, Jassem, Jacek, Wardowska, Anna, and Spodzieja, Marta

Subjects
T cells, IMMUNE checkpoint proteins, PEPTIDES, AMINO acid sequence, IMMUNE response, T cell receptors, MICROPHTHALMIA-associated transcription factor
Abstract

Introduction: The effector function of T cells is regulated via immune checkpoints, activating or inhibiting the immune response. The BTLA-HVEM complex, the inhibitory immune checkpoint, may act as one of the tumor immune escape mechanisms. Therefore, interfering with the binding of these proteins can prove beneficial in cancer treatment. Our study focused on peptides interacting with HVEM at the same place as BTLA, thus disrupting the BTLAHVEM interaction. These peptides’ structure and amino acid sequences are based on the gD protein, the ligand of HVEM. Here, we investigated their immunomodulatory potential in melanoma patients. Methods: Flow cytometry analyses of activation, proliferation, and apoptosis of T cells from patients were performed. Additionally, we evaluated changes within the T cell memory compartment. Results: The most promising compound – Pep(2), increased the percentages of activated T cells and promoted their proliferation. Additionally, this peptide affected the proliferation rate and apoptosis of melanoma cell line in coculture with T cells. Discussion: We conclude that the examined peptide may act as a booster for the immune system. Moreover, the adjuvant and activating properties of the gDderived peptide could be used in a combinatory therapy with currently used ICIbased treatment. Our studies also demonstrate that even slight differences in the amino acid sequence of peptides and any changes in the position of the disulfide bond can strongly affect the immunomodulatory properties of compounds. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Infectious disease prophylaxis and treatment in cancer patients, with particular emphasis on COVID-19. Interdisciplinary position statement of Polish experts.

Author

Rutkowski, Piotr, Cybulska-Stopa, Bożena, Jassem, Jacek, Płużański, Adam, Tomasiewicz, Krzysztof, Wyrwicz, Lucjan, Wysocki, Piotr, Wysocki, Jacek, and Flisiak, Robert

Subjects
TRANSMISSIBLE tumors, COVID-19 pandemic, COMMUNICABLE diseases, THERAPEUTICS, CANCER patients
Abstract

Infectious diseases constitute a significant burden for cancer patients. This became particularly evident during the COVID-19 pandemic. Due to cancer itself and its treatment, the course of infectious diseases in oncology patients is often unpredictable and may negatively affect them. Preventing infectious diseases through a wide range of vaccinations may help maintain the continuity of treatment and constitute an element of holistic patient care. Testing patients with symptoms or suspected infections allows proper treatment and may avoid unfavorable consequences. More education on preventing and treating infectious diseases is necessary to improve the standard of cancer care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Can an Integrative SNP Approach Substitute Standard Identification in Comprehensive Case/Control Analyses?

Author

Papiez, Anna, Skrzypski, Marcin, Szymanowska-Narloch, Amelia, Jassem, Ewa, Maciejewska, Agnieszka, Pawlowski, Ryszard, Dziadziuszko, Rafal, Jassem, Jacek, Rzyman, Witold, Polanska, Joanna, Kacprzyk, Janusz, Series Editor, Pal, Nikhil R., Advisory Editor, Bello Perez, Rafael, Advisory Editor, Corchado, Emilio S., Advisory Editor, Hagras, Hani, Advisory Editor, Kóczy, László T., Advisory Editor, Kreinovich, Vladik, Advisory Editor, Lin, Chin-Teng, Advisory Editor, Lu, Jie, Advisory Editor, Melin, Patricia, Advisory Editor, Nedjah, Nadia, Advisory Editor, Nguyen, Ngoc Thanh, Advisory Editor, Wang, Jun, Advisory Editor, Fdez-Riverola, Florentino, editor, Mohamad, Mohd Saberi, editor, Rocha, Miguel, editor, De Paz, Juan F., editor, and González, Pascual, editor

Published
2019
Full Text
View/download PDF

24. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort

Author

Thunnissen, Erik, Kerr, Keith M., Dafni, Urania, Bubendorf, Lukas, Finn, Stephen P., Soltermann, Alex, Biernat, Wojciech, Cheney, Richard, Verbeken, Erik, Warth, Arne, Marchetti, Antonio, Speel, Ernst-Jan M., Pokharel, Saraswati, Quinn, Anne Marie, Monkhorst, Kim, Navarro, Atilio, Madsen, Line Bille, Tsourti, Zoi, Geiger, Thomas, Kammler, Roswitha, Peters, Solange, Stahel, Rolf A., Rosell, Rafael, Blackhall, Fiona, Molina, Miguel Angel, Weder, Walter, Finn, Stephen, Hiltbrunner, Anita, Marti, Nesa, Polydoropoulou, Varvara, Zygoura, Panagiota, Nicolson, Marianne, Stevenson, David A.J, Mathieson, William, Smit, Egbert, Radonic, Teodora, Rulle, Undine, Curioni, Alessandra, Gray, Steven G., Gately, Kathy, Barr, Martin, Meldgaard, Peter, Madsen, Line B., Savic, Spasenija, Lardinois, Didier, Nackaerts, Kristiaan, Dooms, Christophe, Wauters, Els, Van Der Borght, Sara, Wrona, Ania, Rzyman, Witold, Jassem, Jacek, Dienemann, Hendrik, Muley, Thomas, De Luca, Graziano, di Lorito, Alessia, Dingemans, Anne-Marie, Ruland, Andrea, Ferenczy, Philip, Franklin, Lynsey, Baas, Paul, van de Wiel, Bart, Camps, Carlos, and Martorell, Miguel

Published
2020
Full Text
View/download PDF

25. 606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy

Author

Srivastava, Minu K, primary, Gayevskiy, Velimir, additional, Ma, Vy, additional, Estay, Ivette, additional, Rodas, Miguel Lopez de, additional, Rajendran, Barani Kumar, additional, Hoang, Tien, additional, Ballinger, Marcus, additional, Amin, Reena, additional, Herbst, Roy S, additional, Marinis, Filippo de, additional, Giaccone, Giuseppe, additional, Jassem, Jacek, additional, Spigel, David R, additional, Schalper, Kurt, additional, Koeppen, Hartmut, additional, Shames, David S, additional, Johnston, Robert, additional, Giltnane, Jennifer M, additional, and Nabet, Barzin Y, additional

Published
2023
Full Text
View/download PDF

30. Fertility preservation during oncological treatment.

Author

Kufel-Grabowska, Joanna, Łukaszuk, Krzysztof, Błażek, Magdalena, Jagiełło-Gruszfeld, Agnieszka, Horbaczewska, Anna, Irga-Jaworska, Ninela, Jach, Robert, Jędrzejczak, Piotr, Kopeć, Izabela, Krawczuk-Rybak, Maryna, Krzakowski, Maciej, Pogoda, Katarzyna, Sąsiadek, Maria, Spaczyński, Robert, Urbaniak, Monika, Wojciechowska-Lampka, Elżbieta, Wołczyński, Sławomir, and Jassem, Jacek

Subjects
FERTILITY preservation, EARLY diagnosis, CANCER treatment, REPRODUCTIVE health, MEDICAL care standards
Published
2024
Full Text
View/download PDF

32. Fertility preservation during oncological treatment

Author

Kufel-Grabowska, Joanna, primary, Łukaszuk, Krzysztof, additional, Błażek, Magdalena, additional, Jagiełło-Gruszfeld, Agnieszka, additional, Horbaczewska, Anna, additional, Irga-Jaworska, Ninela, additional, Jach, Robert, additional, Jędrzejczak, Piotr, additional, Kopeć, Izabela, additional, Krawczuk-Rybak, Maryna, additional, Krzakowski, Maciej, additional, Pogoda, Katarzyna, additional, Sąsiadek, Maria, additional, Spaczyński, Robert, additional, Urbaniak, Monika, additional, Wojciechowska-Lampka, Elżbieta, additional, Wołczyński, Sławomir, additional, and Jassem, Jacek, additional

Published
2023
Full Text
View/download PDF

33. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

Author

Stahel, Rolf A., Rosell, Rafael, Blackhall, Fiona, Dafni, Urania, Kerr, Keith M., Molina, Miguel Ángel, Bubendorf, Lukas, Weder, Walter, Thunnissen, Erik, Peters, Solange, Finn, Stephen, Hiltbrunner, Anita, Kammler, Roswitha, Geiger, Thomas, Marti, Nesa, Tsourti, Zoi, Polydoropoulou, Varvara, Zygoura, Panagiota, Smyth, Paul, O’Brien, Cathal, Gray, Steven, Soltermann, Alex, Opitz, Isabelle, Curioni, Alessandra, Savic, Spasenija, Lardinois, Didier, Dingemans, Anne-Marie, Speel, Ernst-Jan M., Ruland, Andrea, Marchetti, Antonio, Di Lorito, Alessia, De Luca, Graziano, Malatesta, Sara, Nonaka, Daisuke, Quinn, Anne Marie, Franklin, Lynsey, Biernat, Wojciech, Wrona, Ania, Rzyman, Witold, Jassem, Jacek, Meldgaard, Peter, Hager, Henrik, Madsen, Line B., Camps, Carlos, Martorell, Miguel, Jantus-Lewintre, Eloisa, Guijarro, Ricardo, Nicolson, Marianne, Stevenson, David A.J., Mathieson, William, Baas, Paul, de Jong, Jeroen, Monkhorst, Kim, Smit, Egbert, van Setten, Coralien, de Langen, Joop, Felip, Enriqueta, Hernandez-Losa, Javier, Sansano, Irene, Cheney, Richard, Pine, Mary Beth, Reid, Mary, Taylor, Elizabeth, Nackaerts, Kristiaan, Dooms, Christophe, Wauters, Els, Van Der Borght, Sara, Dienemann, Hendrik, Muley, Thomas, Warth, Arne, Letovanec, Igor, Speel, Ernst-Jan, Sejda, Aleksandra, Verbeken, Eric, Navarro, Atilio, Dziadziuszko, Rafal, Vansteenkiste, Johan, O'Brien, Cathal, Sherlock, Jon, Schageman, Jeoffrey, Kerr, Keith, and Stahel, Rolf

Published
2018
Full Text
View/download PDF

34. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform

Author

Wu, Natalie C., Wong, Wendy, Ho, Kenneth E., Chu, Victor C., Rizo, Annaliza, Davenport, Simon, Kelly, Devon, Makar, Rosemary, Jassem, Jacek, Duchnowska, Renata, Biernat, Wojciech, Radecka, Barbara, Fujita, Tomoyuki, Klein, Jonathan L., Stonecypher, Mark, Ohta, Shoichiro, Juhl, Hartmut, Weidler, Jodi M., Bates, Michael, and Press, Michael F.

Published
2018
Full Text
View/download PDF

35. Data from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer

Author

Khan, Imran, primary, Gril, Brunilde, primary, Paranjape, Anurag N., primary, Robinson, Christina M., primary, Difilippantonio, Simone, primary, Biernat, Wojciech, primary, Bieńkowski, Michał, primary, Pęksa, Rafał, primary, Duchnowska, Renata, primary, Jassem, Jacek, primary, Brastianos, Priscilla K., primary, Metellus, Philippe, primary, Bialecki, Emilie, primary, Woodroofe, Carolyn C., primary, Wu, Haitao, primary, Swenson, Rolf E., primary, and Steeg, Patricia S., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure S1-S10 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer

Author

Khan, Imran, primary, Gril, Brunilde, primary, Paranjape, Anurag N., primary, Robinson, Christina M., primary, Difilippantonio, Simone, primary, Biernat, Wojciech, primary, Bieńkowski, Michał, primary, Pęksa, Rafał, primary, Duchnowska, Renata, primary, Jassem, Jacek, primary, Brastianos, Priscilla K., primary, Metellus, Philippe, primary, Bialecki, Emilie, primary, Woodroofe, Carolyn C., primary, Wu, Haitao, primary, Swenson, Rolf E., primary, and Steeg, Patricia S., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 1 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer

Author

Khan, Imran, primary, Gril, Brunilde, primary, Paranjape, Anurag N., primary, Robinson, Christina M., primary, Difilippantonio, Simone, primary, Biernat, Wojciech, primary, Bieńkowski, Michał, primary, Pęksa, Rafał, primary, Duchnowska, Renata, primary, Jassem, Jacek, primary, Brastianos, Priscilla K., primary, Metellus, Philippe, primary, Bialecki, Emilie, primary, Woodroofe, Carolyn C., primary, Wu, Haitao, primary, Swenson, Rolf E., primary, and Steeg, Patricia S., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Material and Methods from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer

Author

Khan, Imran, primary, Gril, Brunilde, primary, Paranjape, Anurag N., primary, Robinson, Christina M., primary, Difilippantonio, Simone, primary, Biernat, Wojciech, primary, Bieńkowski, Michał, primary, Pęksa, Rafał, primary, Duchnowska, Renata, primary, Jassem, Jacek, primary, Brastianos, Priscilla K., primary, Metellus, Philippe, primary, Bialecki, Emilie, primary, Woodroofe, Carolyn C., primary, Wu, Haitao, primary, Swenson, Rolf E., primary, and Steeg, Patricia S., primary

Published
2023
Full Text
View/download PDF

40. Platelet-Based Liquid Biopsies through the Lens of Machine Learning

Author

Cygert, Sebastian, primary, Pastuszak, Krzysztof, additional, Górski, Franciszek, additional, Sieczczyński, Michał, additional, Juszczyk, Piotr, additional, Rutkowski, Antoni, additional, Lewalski, Sebastian, additional, Różański, Robert, additional, Jopek, Maksym Albin, additional, Jassem, Jacek, additional, Czyżewski, Andrzej, additional, Wurdinger, Thomas, additional, Best, Myron G., additional, Żaczek, Anna J., additional, and Supernat, Anna, additional

Published
2023
Full Text
View/download PDF

42. Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer

Author

Duchnowska, Renata, Jarząb, Michał, Żebracka-Gala, Jadwiga, Matkowski, Rafał, Kowalczyk, Anna, Radecka, Barbara, Kowalska, Małgorzata, Pfeifer, Aleksandra, Foszczyńska-Kłoda, Małgorzata, Musolino, Antonino, Czartoryska-Arłukowicz, Bogumiła, Litwiniuk, Maria, Surus-Hyla, Anna, Szabłowska-Siwik, Sylwia, Karczmarek-Borowska, Bożenna, Dębska-Szmich, Sylwia, Głodek-Sutek, Beata, Sosińska-Mielcarek, Katarzyna, Chmielowska, Ewa, Kalinka-Warzocha, Ewa, Olszewski, Wojciech P., Patera, Janusz, Żawrocki, Anton, Pliszka, Agnieszka, Tyszkiewicz, Tomasz, Rusinek, Dagmara, Oczko-Wojciechowska, Małgorzata, Jassem, Jacek, and Biernat, Wojciech

Published
2017
Full Text
View/download PDF

43. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer

Author

Yu, Hui, Batenchuk, Cory, Badzio, Andrzej, Boyle, Theresa A., Czapiewski, Piotr, Chan, Daniel C., Lu, Xian, Gao, Dexiang, Ellison, Kim, Kowalewski, Ashley A., Rivard, Christopher J., Dziadziuszko, Rafal, Zhou, Caicun, Hussein, Maen, Richards, Donald, Wilks, Sharon, Monte, Marc, Edenfield, William, Goldschmidt, Jerome, Page, Ray, Ulrich, Brian, Waterhouse, David, Close, Sandra, Jassem, Jacek, Kulig, Kimary, and Hirsch, Fred R.

Published
2017
Full Text
View/download PDF

44. Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients.

Author

Cytawa, Wojciech, Hendel, Robin, Tomasik, Bartłomiej, Weinzierl, Franz-Xaver, Bley, Thorsten, Jassem, Jacek, Schirbel, Andreas, Buck, Andreas K., Bundschuh, Ralph A., Hartrampf, Philipp E., Werner, Rudolf A., and Lapa, Constantin

Subjects
CASTRATION-resistant prostate cancer, PROSTATE cancer patients, LUTEINIZING hormone releasing hormone, PATIENT experience, LUTETIUM compounds
Abstract

Purpose: The aim of this study was to investigate very early radiographic PSMA PET response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) and to assess its role in predicting overall response and survival. Methods: This retrospective study enrolled 40 mCRPC patients who were treated with a median of 3 (2–9) [177Lu]Lu-PSMA I&T RLT cycles. Biochemical response was based on the relative change of serum PSA according to PCWG3 criteria, while radiographic response referred to the relative change of PSMA-derived total viable tumor volumes expressed as total lesion PSMA (TLP). Results: After one cycle of RLT, biochemical partial response (PR) was seen in 8/40 (20.0%), stable disease (SD) in 22/40 (55.0%), and progressive disease (PD) in 10/40 (25%) patients. In PSMA PET, very early molecular PR was observed in 12 (30.0%), SD in 19 (47.5%), and PD in 9 (22.5%) subjects. The PSA and TLP nadir were achieved after a median of 1 (1–5) and 2 (1–6) cycles, respectively. Nineteen (47.5%) patients showed overall biochemical PR, 11 (27.5%) had SD, and 10 (25%) experienced PD. In PSMA-directed PET, 4 patients experienced molecular complete response (CR), 24 (60.0%) had PR, 4 (10.0%) SD, and 8 (20.0%) PD. Early biochemical or radiographic response was not associated with longer overall survival (OS). Overall biochemical responders had a nearly significantly longer median OS (22.7 months) than non-responders (14.4 months, p = 0.08). Early PSA progression was associated with shorter OS (12.2 months), compared to biochemical SD/PR (18.7 months, p = 0.09). Conclusion: In this retrospective cohort, there was no association between early PSMA PET radiographic response and overall survival; hence, treatment should not be prematurely discontinued. In contrast, early PSA progression after one cycle of [177Lu]Lu-PSMA I&T RLT was an indicator of overall progression and poor clinical outcome. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Supplementary Data from An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer

Author

Roepman, Paul, primary, Jassem, Jacek, primary, Smit, Egbert F., primary, Muley, Thomas, primary, Niklinski, Jacek, primary, van de Velde, Tony, primary, Witteveen, Anke T., primary, Rzyman, Witold, primary, Floore, Arno, primary, Burgers, Sjaak, primary, Giaccone, Giuseppe, primary, Meister, Michael, primary, Dienemann, Hendrik, primary, Skrzypski, Marcin, primary, Kozlowski, Miroslaw, primary, Mooi, Wolter J., primary, and van Zandwijk, Nico, primary

Published
2023
Full Text
View/download PDF

46. Data from Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer

Author

Glubb, Dylan M., primary, Cerri, Elisa, primary, Giese, Alexandra, primary, Zhang, Wei, primary, Mirza, Osman, primary, Thompson, Emma E., primary, Chen, Peixian, primary, Das, Soma, primary, Jassem, Jacek, primary, Rzyman, Witold, primary, Lingen, Mark W., primary, Salgia, Ravi, primary, Hirsch, Fred R., primary, Dziadziuszko, Rafal, primary, Ballmer-Hofer, Kurt, primary, and Innocenti, Federico, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Tables 2 - 4 from FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

Author

Wynes, Murry W., primary, Hinz, Trista K., primary, Gao, Dexiang, primary, Martini, Michael, primary, Marek, Lindsay A., primary, Ware, Kathryn E., primary, Edwards, Michael G., primary, Böhm, Diana, primary, Perner, Sven, primary, Helfrich, Barbara A., primary, Dziadziuszko, Rafal, primary, Jassem, Jacek, primary, Wojtylak, Szymon, primary, Sejda, Aleksandra, primary, Gozgit, Joseph M., primary, Bunn, Paul A., primary, Camidge, D. Ross, primary, Tan, Aik-Choon, primary, Hirsch, Fred R., primary, and Heasley, Lynn E., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure Legends from Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner

Author

Palmieri, Diane, primary, Duchnowska, Renata, primary, Woditschka, Stephan, primary, Hua, Emily, primary, Qian, Yongzhen, primary, Biernat, Wojciech, primary, Sosińska-Mielcarek, Katarzyna, primary, Gril, Brunilde, primary, Stark, Andreas M., primary, Hewitt, Stephen M., primary, Liewehr, David J., primary, Steinberg, Seth M., primary, Jassem, Jacek, primary, and Steeg, Patricia S., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner

Author

Palmieri, Diane, primary, Duchnowska, Renata, primary, Woditschka, Stephan, primary, Hua, Emily, primary, Qian, Yongzhen, primary, Biernat, Wojciech, primary, Sosińska-Mielcarek, Katarzyna, primary, Gril, Brunilde, primary, Stark, Andreas M., primary, Hewitt, Stephen M., primary, Liewehr, David J., primary, Steinberg, Seth M., primary, Jassem, Jacek, primary, and Steeg, Patricia S., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table 5 from Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer

Author

Glubb, Dylan M., primary, Cerri, Elisa, primary, Giese, Alexandra, primary, Zhang, Wei, primary, Mirza, Osman, primary, Thompson, Emma E., primary, Chen, Peixian, primary, Das, Soma, primary, Jassem, Jacek, primary, Rzyman, Witold, primary, Lingen, Mark W., primary, Salgia, Ravi, primary, Hirsch, Fred R., primary, Dziadziuszko, Rafal, primary, Ballmer-Hofer, Kurt, primary, and Innocenti, Federico, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results